Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers

ABSTRACT: RATIONALE: A disease management program may be more effective than standard therapy in improving quality of life and controlling symptoms in patients with cancer. PURPOSE: This clinical trial is studying a disease management program to see how well it works compared with usual care in patients with stage III or stage IV lung cancer, stage III or stage IV pancreatic cancer, stage III or stage IV ovarian cancer, or stage III or stage IV colorectal cancer, and their caregivers.

DISEASE(S): Ovarian Cancer,Lung Cancer,Carcinoma, Ovarian Epithelial,Colorectal Cancer,Colorectal Neoplasms,Ovarian Neoplasms,Pancreatic Cancer,Pancreatic Neoplasms,Lung Neoplasms

PROVIDER: 2055911 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Gene expression profiles in bone marrow of human gastric adenocarcinoma at stage III and stage IV

2013-10-22 | GSE41801 | GEO

Gene expression profiles in bone marrow of human gastric adenocarcinoma at stage III and stage IV

Project description:A secreted factor in bone marrow associated with metastatic gastric cancer was indentified through expression profiling in bone marrow of stage III and stage IV gastric adenocarcinoma. In the study presented here, bone marrow samples from patients with stage III or stage IV gastric adenocarcinoma were used to acquire expression profiles.

2013-10-22 | E-GEOD-41801 | biostudies-arrayexpress

Late stage ovarian cancer gene expression profiles

Project description:Gene expression profiling on 63 stage III-IV papillary serous ovarian cancer samples resected during primary debulking at the University of Turin, Italy. Only the primary ovarian mass and no metastases were included in this analysis. The study focused on ovarian cancer chemokine expressions

2014-12-04 | GSE62873 | GEO

PFNF54-Pfs16-GFP-LUC gametocytes treated at early stage or late stage development with compound MMV666810 or MMV674850

Project description:Plasmodium falciparum gametocytes can often show differential drug responses depending on their stage of development. Here, the transcriptomic response of early stage (Stage II-III) and late stage (Stage IV-V) gametocytes was evaluated following treatment with chemical compounds that show differential killing activity between early and late-stage gametocytes.

2021-02-19 | GSE167068 | GEO

Transcription profiling of ovarium cancer samples from patients with tumors of different stages and sensitivity to platinum chemotherapy treatment

Project description:We investigated whether prognostic information is reflected in the expression patterns of ovarian carcinoma samples. RNA obtained from seven FIGO stage I without recurrence, seven platin-sensitive advanced-stage (III or IV), and six platin-resistant advanced-stage ovarian tumors was hybridized on a complementary DNA microarray with 21,372 spotted clones. The results revealed that a considerable number of genes exhibit nonaccidental differential expression between the different tumor classes. Principal component analysis reflected the differences between the three tumor classes and their order of transition. Using a leave-one-out approach together with least squares support vector machines, we obtained an estimated classification test accuracy of 100% for the distinction between stage I and advanced-stage disease and 76.92% for the distinction between platin-resistant versus platin-sensitive disease in FIGO stage III/IV. These results indicate that gene expression patterns could be useful in clinical management of ovarian cancer.<br> KEYWORDS: clinical, FIGO stage, microarrays, ovarian cancer, platin resistance.

2007-02-10 | E-MEXP-979 | biostudies-arrayexpress

Late stage ovarian cancer gene expression profiles

2014-10-31 | E-GEOD-62873 | biostudies-arrayexpress

Gene expression profiles to predict recurrence in stage II and III colon cancer

Project description:Purpose: The present study aimed to develop a classification model to predict recurrence in stage II and III colon cancer, using a previously published 128-gene signature on external and independent material. Experimental Design: Microarray gene expression data from 148 patients (37 Danish patients and 111 patients retrieved from the Gene Expression Omnibus, GSE17536) with stage II and III colon cancer were analyzed using Affymetrix Arrays (Affymetrix, Santa Clara, USA). Based on a known 128-gene signature, a classification model was created with the random forest method, using a training set consisting of stage I colon cancers (with localized disease and a good prognosis) and stage IV colon cancers (with metastasis and a poor prognosis). The classifier were built to predict stage II and III colon cancers as either stage I-like (good prognosis) or stage IV-like (poor prognosis). Results: The 3-year relapse-free survival probability (RFS) of stage III patients predicted to have a good prognosis was 79% compared to 55% of patients with a poor prognosis (P = 0.177, log-rank test). The classification model could not stratify stage II colon cancer. The complete dataset representing: (1) the 37 Danish patients (2) the 111 patients retrieved from Series GSE17536 (re-used data), is linked below as a supplementary file. Tumor samples were obtained from 37 patients with stage II and III colon cancer, who underwent colon resection at the Department of Surgery, Roskilde Hospital, Denmark and the Department of Surgery, Bispebjerg Hospital, Denmark between 2001 and 2008. Purified tumor RNA was reverse-transcribed, labelled and hybridized to Affymetrix Human Genome U133 Plus 2.0 GeneChip Array (Affymetrix, Santa Clara, USA) according to the manufacturers instructions and scanned at the RH Microarray Center, Rigshospitalet, University of Copenhagen.

2011-08-31 | E-GEOD-31595 | biostudies-arrayexpress

Gene expression in stage III colorectal cancer

Project description:Gene expression in stage III colorectal cancer

| PRJNA610891 | ENA

Targeted sequencing data and shallow whole genome sequencing data of Follicular lymphoma.

Project description:Contain data of 2 studies 1: 82 nodal stage 1 FL cases and 139 stage III/IV cases 2: 44 watch and wait stage III/IV and 46 Immediate treatment stage III/IV targeted sequencing data of 369 genes and 12 translocation regions whole genome shallow sequencing data

| EGAS00001005755 | EGA

miRNA profiling of late stage metastatic Her2+ breast cancer

Project description:We have assayed differential miRNA expression between late stage (stage IV) metastatic Her2+ and Her2- breast cancer.

2010-04-29 | GSE20066 | GEO